(original) (raw)

TY - JOUR AU - Spohn, Gunther AU - Jennings, Gary T. AU - Martina, Byron EE AU - Keller, Iris AU - Beck, Markus AU - Pumpens, Paul AU - Osterhaus, Albert DME AU - Bachmann, Martin F. PY - 2010 DA - 2010/07/06 TI - A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice JO - Virology Journal SP - 146 VL - 7 IS - 1 AB - Since its first appearance in the USA in 1999, West Nile virus (WNV) has spread in the Western hemisphere and continues to represent an important public health concern. In the absence of effective treatment, there is a medical need for the development of a safe and efficient vaccine. Live attenuated WNV vaccines have shown promise in preclinical and clinical studies but might carry inherent risks due to the possibility of reversion to more virulent forms. Subunit vaccines based on the large envelope (E) glycoprotein of WNV have therefore been explored as an alternative approach. Although these vaccines were shown to protect from disease in animal models, multiple injections and/or strong adjuvants were required to reach efficacy, underscoring the need for more immunogenic, yet safe DIII-based vaccines. SN - 1743-422X UR - https://doi.org/10.1186/1743-422X-7-146 DO - 10.1186/1743-422X-7-146 ID - Spohn2010 ER -